Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)

The National Institutes of Health, within the U.S. Department of Health and Human Services, through the National Institute of Arthritis and Musculoskeletal and Skin Diseases, has announced a forecasted funding opportunity titled Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed). NIAMS is a federal research institute focused on supporting studies related to arthritis, musculoskeletal disorders, and skin diseases. This opportunity is designed to encourage investigators to leverage existing clinical research investments by conducting ancillary studies that expand the scientific value of ongoing clinical projects. Although the parent clinical studies may fall outside the direct mission of NIAMS, any proposed ancillary study must align with NIAMS priorities and contribute to advancing knowledge in its mission areas. The purpose of this opportunity is to maximize the utility of existing clinical research infrastructure, including well-characterized patient cohorts, datasets, and biological samples. By funding ancillary studies, NIAMS aims to support innovative research questions that can be addressed without initiating entirely new clinical trials. This approach allows researchers to generate additional insights efficiently while building on already funded and operational clinical projects. The funding mechanism specified is an R21 grant, which typically supports exploratory and developmental research projects. The estimated total program funding for this opportunity is 600,000 dollars, with approximately two awards anticipated. Specific award ceilings and floors are not provided in the forecast, indicating that applicants should monitor the full Notice of Funding Opportunity upon release for detailed budget guidance. There is no cost sharing or matching requirement, which reduces financial barriers for applicants. Funding is expected to support activities that involve data analysis, use of existing clinical samples, and other ancillary research efforts, but not new clinical trials, as clinical trials are explicitly not allowed under this mechanism. Eligibility for this opportunity is broad and includes a wide range of applicant types. Eligible entities include private and public institutions of higher education, nonprofit organizations with 501(c)(3) status, small and large businesses, state and local governments, independent school districts, tribal governments, tribal organizations, and public housing authorities. This inclusive eligibility structure reflects NIH’s commitment to supporting diverse research institutions and fostering collaboration across sectors. Applicants are encouraged to form partnerships that bring together expertise in clinical research and disease-specific knowledge aligned with NIAMS priorities. At the time of this forecast notice, applications are not yet being solicited. The forecast is intended to provide advance notice so that potential applicants can begin preparing competitive proposals and establishing collaborations. The estimated application due date is April 6, 2026, with an estimated posting date of February 4, 2026. Awards are expected to be made by December 4, 2026, with project start dates aligned to the same timeline. No pre-application requirements such as letters of intent are specified in the forecast. The evaluation criteria and detailed submission requirements will be outlined in the forthcoming Notice of Funding Opportunity. However, applicants can anticipate that proposals will be assessed based on scientific merit, alignment with NIAMS mission areas, feasibility of leveraging existing clinical resources, and the strength of collaborative partnerships. Interested applicants may contact the program officer, Heiyoung Park, for additional information or clarification. This forecasted opportunity underscores NIH’s emphasis on efficient use of existing research investments and encourages investigators to proactively develop innovative ancillary studies in preparation for the formal funding announcement.